3-[(2-萘磺酰基)氨基]丙酸 | 100394-14-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-[(2-萘磺酰基)氨基]丙酸
• 英文名称: 3-(naphthalene-2-sulfonylamino)-propionic acid
• 英文别名: N-(naphthalene-2-sulfonyl)-β-alanine；N-(Naphthalin-2-sulfonyl)-β-alanin；3-[(2-Naphthylsulfonyl)amino]propanoic acid；3-(naphthalen-2-ylsulfonylamino)propanoic acid
• CAS: 100394-14-7
• 化学式: C₁₃H₁₃NO₄S
• mdl: MFCD01249750
• 分子量: 279.317
• InChiKey: ZARBMGXIZPSUAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  哌嗪 、 3-[(2-萘磺酰基)氨基]丙酸 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以54%的产率得到N,N'-(3,3'-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))dinaphthalene-2-sulfonamide
  参考文献：
  名称：

  In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase

  摘要：

  A structure-based virtual screening of commercial compounds was carried out on the HCV NS3 helicase structure, with the aim to identify novel inhibitors of HCV replication. Among a selection of 13 commercial structures, one compound was found to inhibit the subgenomic HCV replicon in the low micromolar range. Different series of new piperazine-based analogues were designed and synthesised, and among them, several novel structures exhibited antiviral activity in the HCV replicon assay. Some of the new compounds were also found to inhibit HCV NS3 helicase function in vitro, and one directly bound NS3 with a dissociation constant of 570 +/- 270 nM. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.10.043
• 作为产物：
  描述：

  萘-2-磺酰胺 在 sodium hydroxide 、 苄基三甲基氢氧化铵 作用下， 生成 3-[(2-萘磺酰基)氨基]丙酸
  参考文献：
  名称：

  Misra; Asthana, Journal fur praktische Chemie (Leipzig 1954), 1957, vol. <4> 4, p. 270,274

  摘要：

  DOI：

文献信息

• [EN] COMPSTATIN ANALOGS WITH IMPROVED POTENCY AND PHARMACOKINETIC PROPERTIES<br/>[FR] ANALOGUES DE COMPSTATINE DE PUISSANCE ET DE PROPRIÉTÉS PHARMACOCINÉTIQUES AMÉLIORÉES
  申请人：UNIV PENNSYLVANIA

  公开号：WO2015142701A1

  公开（公告）日：2015-09-24

  Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds include a modified compstatin peptide or analog thereof, comprising an added N-terminal component that improves (1) the binding affinity of the peptide to C3, C3b or C3c and/or (2) the plasma stability and/or plasma residence time of the peptide, as compared with an unmodified compstatin peptide under equivalent conditions. Methods of improving the C3 binding of compstatin or compstatin analogs are also disclosed, as well as methods of designing compstatin analogs with improved C3 binding.

  本发明涉及包含能够结合C3蛋白并抑制补体激活的肽的化合物。这些化合物包括一种经过修改的compstatin肽或其类似物，其中包括一个添加的N-末端组分，该组分改善了肽与C3、C3b或C3c的结合亲和力和/或与未经修改的compstatin肽在等效条件下相比的血浆稳定性和/或血浆停留时间。还公开了改善compstatin或compstatin类似物的C3结合的方法，以及设计具有改善C3结合的compstatin类似物的方法。
• Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
  申请人：ZENECA LIMITED

  公开号：US20020119968A1

  公开（公告）日：2002-08-29

  The invention concerns compounds of formula (I) 1 wherein each of G 1 , G 2 and G 3 is CH or N; m is 1 or 2; R 1 includes hydrogen, halogeno and (1-4C)alkyl; M 1 is a group of the formula: NR 2 —L 1 —T 1 R 3 in which R 2 and R 3 together form a (1-4C)alkylene group, L 1 includes (1-4C)alkylene, and T 1 is CH or N; A may be a direct link; M 2 is a group of the formula: (T 2 R 4 ) r —L 2 —T 3 R 5 in which r is 0 or 1, each of T 2 and T 3 is CH or N, each of R 4 and R 5 is hydrogen or (1-4C)alkyl, or R 4 and R 5 together form a (1-4C)alkylene group, and L 2 includes (1-4C)alkylene; M 3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

  本发明涉及式(I)的化合物，其中G1、G2和G3中的每一个是CH或N；m为1或2；R1包括氢、卤素和(1-4C)烷基；M1是公式NR2-L1-T1R3的基团，在其中R2和R3共同形成一个(1-4C)烷基，L1包括(1-4C)烷基，T1是CH或N；A可以是直接连接；M2是公式(T2R4)r-L2-T3R5的基团，在其中r为0或1，T2和T3中的每一个是CH或N，R4和R5中的每一个是氢或(1-4C)烷基，或者R4和R5共同形成一个(1-4C)烷基，L2包括(1-4C)烷基；M3可以是直接连接到X；X包括磺酰基；Q包括萘基和杂环基；或其药学上可接受的盐；制备它们的方法，含有它们的制药组合物以及它们作为抗血栓或抗凝剂剂的用途。
• Compstatin analogs with improved pharmacokinetic properties
  申请人：The Trustees of the University of Pennsylvania

  公开号：US10174079B2

  公开（公告）日：2019-01-08

  Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.

  本研究公开了由能够结合 C3 蛋白并抑制补体激活的多肽组成的化合物。这些化合物包括康普司他丁类似物，其中 N 端含有添加或取代的成分，与同等条件下未修饰的康普司他丁肽相比，可提高（1）肽与 C3 或其片段的结合亲和力；（2）肽在水性液体中的溶解度；（3）肽的血浆稳定性；（4）肽的体内保留率和（或）（5）肽的生物利用度。此外，还公开了这些化合物的药物组合物和使用方法。
• Lythgoe et al., Biochemical Journal, 1940, vol. 34, p. 1335,1337
  作者：Lythgoe et al.

  DOI：——

  日期：——
• Pantothenic Acid. IV. Formation of β-Alanine by Cleavage
  作者：Harry H. Weinstock、Herschel K. Mitchell、Ernest F. Pratt、Roger J. Williams

  DOI：10.1021/ja01875a029

  日期：1939.6